128 related articles for article (PubMed ID: 37886501)
1. Simultaneous Inhibition of PI3K and PAK in Preclinical Models of Neurofibromatosis Type 2-related Schwannomatosis.
Fernandez-Valle C; Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin H
Res Sq; 2023 Oct; ():. PubMed ID: 37886501
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
[TBL] [Abstract][Full Text] [Related]
3. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.
Huegel J; Dinh CT; Martinelli M; Bracho O; Rosario R; Hardin H; Estivill M; Griswold A; Gultekin S; Liu XZ; Fernandez-Valle C
Oncotarget; 2022; 13():890-904. PubMed ID: 35875610
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
[TBL] [Abstract][Full Text] [Related]
5. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
[TBL] [Abstract][Full Text] [Related]
6. A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.
Petrilli AM; Fuse MA; Donnan MS; Bott M; Sparrow NA; Tondera D; Huffziger J; Frenzel C; Malany CS; Echeverri CJ; Smith L; Fernández-Valle C
Am J Transl Res; 2014; 6(5):471-93. PubMed ID: 25360213
[TBL] [Abstract][Full Text] [Related]
7. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
8. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions.
Yuan R; Wang B; Wang Y; Liu P
Oncol Ther; 2024 Jun; 12(2):257-276. PubMed ID: 38760612
[TBL] [Abstract][Full Text] [Related]
11. Merlin-Deficient Schwann Cells Are More Susceptible to Radiation Injury than Normal Schwann Cells In Vitro.
Cohen E; Pena S; Mei C; Bracho O; Marples B; Elsayyad N; Goncalves S; Ivan M; Monje PV; Liu XZ; Fernandez-Valle C; Telischi F; Dinh CT
J Neurol Surg B Skull Base; 2022 Jun; 83(3):228-236. PubMed ID: 35769808
[No Abstract] [Full Text] [Related]
12. Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.
Mercado-Pimentel ME; Miller C; Rolph DN; Villalobos EF; Dunn AM; Mohan PM; Igarashi S; Liu X; Yrun-Duffy M; Patel NK; Read CM; Francis RH; Lane AI; Murugesh S; Jacob A
Otol Neurotol; 2017 Jan; 38(1):139-146. PubMed ID: 27755359
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
14. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
Bhattacharyya S; Oblinger JL; Beauchamp RL; Yin Z; Erdin S; Koundinya P; Ware AD; Ferrer M; Jordan JT; Plotkin SR; Xu L; Chang LS; Ramesh V
Neuro Oncol; 2023 Sep; 25(9):1617-1630. PubMed ID: 36806881
[TBL] [Abstract][Full Text] [Related]
15. The comparable tumour microenvironment in sporadic and
Gregory GE; Jones AP; Haley MJ; Hoyle C; Zeef LAH; Lin IH; Coope DJ; King AT; Evans DG; Paszek P; Couper KN; Brough D; Pathmanaban ON
Brain Commun; 2023; 5(4):fcad197. PubMed ID: 37680691
[TBL] [Abstract][Full Text] [Related]
16. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
[TBL] [Abstract][Full Text] [Related]
17. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Sagers JE; Beauchamp RL; Zhang Y; Vasilijic S; Wu L; DeSouza P; Seist R; Zhou W; Xu L; Ramesh V; Stankovic KM
Sci Rep; 2020 Mar; 10(1):4211. PubMed ID: 32144278
[TBL] [Abstract][Full Text] [Related]
19. p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
Chow HY; Stepanova D; Koch J; Chernoff J
PLoS One; 2010 Nov; 5(11):e13791. PubMed ID: 21072183
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]